Gene therapy for colorectal cancer

Bibliography

• FERLAY J, BRAY F, PISANI P, PARKIN DM: Globocan 2000. Cancer incidence, mortality and prevalence worldwide, version 1.0. IARC CancerBase No.5. IARCPress, Lyon (2001).
   Google Scholar
• EDWARDS BK, HOWE HL, RIES LAG et al.: Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on US cancer burden. Cancer (2002) 94:2766–2792.
   PubMed Web of Science ®Google Scholar
• CHO KR, VOGELSTEIN B: Genetic alterations in the adenoma-carcinoma sequence. Cancer (1992) 70:1727–1731.
   PubMed Web of Science ®Google Scholar
• FEARON ER, VOGELSTEIN B: A genetic model for colorectal tumorigenesis. Cell (1990) 61:759–767.
   PubMed Web of Science ®Google Scholar
• BOYEL P, LEON ME: Epidemiology of colorectal cancer. Br. Med. Bull. (2002) 64:1–25.
   PubMed Web of Science ®Google Scholar
• ELMA N, KILLI RM, SEVER A: Colorectal carcinoma: radiological diagnosis and staging. Ear: Radial. (2002) 42:206–223.
   Web of Science ®Google Scholar
• SCHEELE J, STANG R, ALTENDORF-HOFMANN A, PAUL M: Resection of colorectal liver metastases. World I Stag. (1995) 19:59–71.
   Web of Science ®Google Scholar
• MINAGAWA M, MAKUUCHI M, TORZILLI G et al.: Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer. Ann. Surg. (2000) 231:487–499.
   PubMed Web of Science ®Google Scholar
• JAMISON RL, DONOHUE JH, NAGORNEY DM, ROSEN CB, HARMSEN WS, ILSTRUP DM: Hepatic resections for metastatic colorectal cancer. Results in cure for some patients. Arch. Surg. (1997) 132:505–511.
   Google Scholar
• MID GLEY R, KERR DJ: Seminar in colorectal cancer. Lancet (1999) 353:391–399.
   PubMed Web of Science ®Google Scholar
• SALTZ LB, COX JV, BLANKE C et al:Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl. I Med. (2000) 343:905–914.
   PubMed Web of Science ®Google Scholar
• DOUILLARD JY, CUNNINGHAM D, ROTH AD et al.: Irinotecan combined with fluorouracil compared with fluouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet(2000) 355:1041–1047.
   PubMed Web of Science ®Google Scholar
• DE GRAMONT A, FIGER A, SEYMOUR M et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.j Clin. Oncol (2000) 18:2938–2947.
   PubMed Web of Science ®Google Scholar
• PALMER DH, CHEN MJ, KERR DJ: Gene therapy for colorectal cancer. Br. Med. Bull. (2002) 64:201–225.
   PubMed Web of Science ®Google Scholar
• VAN ETTEN B, TEN HAGEN TL, DE VRIES MR, AMBAGTSHEER G, HUET T, EGGERMONT AM: Prerequisites for effective adenovirus mediated gene therapy of colorectal liver metastases in the rat using an intracellular neutralizing antibody to p21-Ras. Br. Cancer (2002) 86:436–442.
   Google Scholar
• HARRIS MP, SUTJIPTO S, WILLS KN et al: Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene The]: (1996) 3:121–130.
   PubMed Web of Science ®Google Scholar
• •Animal experiment to demonstrate the therapeutic efficacy of gene therapy using wild-type p53 tumour suppressor gene.
   Google Scholar
• VENOOK AP, BERGSLAND EK, RING E et al: Gene therapy of colorectal liver metastasis using recombinant adenovirus encoding wt p53 (5CH58500) via hepatic artery infusion: a Phase I study. Proc. Am.Soc. Gin. Oncol New York, USA (1998) 17:431a.
   Google Scholar
• •Clinical trial (Phase I) of gene therapy using wild-type p53 tumour suppressor gene for patients with colorectal liver metastasis. No severe adverse events.
   Google Scholar
• BURROWS FJ, GORE M, SMILEY WR et al.: Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells. Cancer Gene The]: (2002) 9:87–95.
   PubMed Web of Science ®Google Scholar
• HUBER BE, AUSTIN EA,RICHARDS CA, DAVIS ST, GOOD SS: Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. USA (1994) 91:8302–8306.
   PubMed Web of Science ®Google Scholar
• CRYSTAL RG, HIRSCHOWITZ E, LIEBERMAN M et al.: Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum. Gene The]: (1997) 8:985–1001.
   Google Scholar
• HARVEY BG, MARONI J,O'DONOGHUE KA et al: Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum. Gene The]: (2002) 13:15–63.
   PubMed Web of Science ®Google Scholar
• LINK JR CJ, LEVY JP, MCCANN LZ, MOORMAN DW: Gene therapy for colon cancer with the herpes simplex thymidine kinase gene. Surg. Oncol (1997) 64:289–294.
   Web of Science ®Google Scholar
• •Animal experiment to demonstrate the therapeutic efficacy of suicide gene therapy using herpes simplex virus thymidine kinase gene and gancidovir. Tumour destruction is observed even when gene transfer is effective only to a small portion of the tumour (bystander effect).
   Google Scholar
• SUNG MW, YEH HC, THUNG SN et al: Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a Phase I clinical trial. MM. Ther. (2001) 4:182–191.
   PubMed Web of Science ®Google Scholar
• ••Clinical trial (Phase I) of suicide genetherapy using herpes simplex thymidine kinase gene and gancidovir for patients with colorectal liver metastasis. No severe adverse events.
   Google Scholar
• GREEN NK, YOUNGS DJ,NEOPTOLEMOS JP et al: Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin 1 yl) 2,4 dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Titer. (1997) 4:229–238.
   PubMed Web of Science ®Google Scholar
• •In vitro experiment to demonstrate the therapeutic efficacy of suicide gene therapy using E. coil nitroreductase gene and CB1954.
   Google Scholar
• MCNEISH IA, GREEN NK,GILLIGAN MG et al.: Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E coif nitroreductase and CB1954. Gene Ther. (1998) 5:1061–1069.
   Google Scholar
• CHUNG-FAYE G, PALMER D, ANDERSON D et al.: Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: A Phase I and pharmacokinetic study of its prodrug, CB1954. Clin. Cancer Res. (2001) 7:2662–2668.
   PubMed Web of Science ®Google Scholar
• FAKHRAI H, SHAWLER DL,GJERSET R et al.: Cytokine gene therapy with interleukin-2-transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. Hum. Gene Ther. (1995) 6:591–601.
   Google Scholar
• FEARON ER, PARDOLL DM, ITAYA T et al.: Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell (1990) 60:397–403.
   PubMed Web of Science ®Google Scholar
• SOBOL RE, SHAWLER DL, CARSON C et al.: Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and geneticallyengineered fibroblasts: A Phase I study.Clin. Cancer Res. (1999) 5:2359–2365.
   Google Scholar
• •Clinical trial (Phase I) of irmrtunogene therapy using interleukin-2 gene for patients with colorectal cancer. No severe adverse events.
   Google Scholar
• SCHMIDT-WOLF IGH, FINKE S, TROJANECK B et al.: Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. ELI: Cancer (1999) 81:1009–1016.
   Web of Science ®Google Scholar
• GALANIS E, HERSH EM, STOPECK AT et al.: Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: Phase I/II experience. J. Clin. Oncol (1999) 17:3313–3323.
   Google Scholar
• GILLIGAN MG, KNOX P, WEEDON S et al.: Adenoviral delivery of B7-1 (CD80) increase the immunogenicity of human ovarian and cervical carcinoma cells. Gene Ther. (1998) 5:965–974.
   PubMed Web of Science ®Google Scholar
• RUBIN J, GALANIS E, PITOT HC et al: Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer on an allogeneichistocompatibility antigen, HLA-B7. Gene Ther. (1997) 4:419–425.
   PubMed Web of Science ®Google Scholar
• STOPECK AT, JONES A, HERSH EM et al.: Phase II study of direct intralesional gene transfer of Allovectin-7, an HLA-B7/ beta 2-microblobulin DNA-liposome complex, in patients with metastatic melanoma. Clin. Cancer Res. (2001) 7:2285–2291.
   PubMed Web of Science ®Google Scholar
• CHUNG-FAYE GA, KERR DJ,YOUNG LS, SEARLE PF: Gene therapy strategies for colon cancer. Ma Med. Today (2000) 6:82–87.
   PubMedGoogle Scholar
• KANTOR J, IRVINE K, ABRAMS S, KAUFMAN H, DIPOETRO J,SCHLOM J: Anti-tumor activity and immune responses induced by a recombinant CEA-vaccinia virus vaccine. J. Natl. Cancer Inst. (1992) 84:1084–1091.
   PubMed Web of Science ®Google Scholar
• BRAMSON JL, WAN YH: The efficacy of genetic vaccination is dependent upon the nature of the vector system and antigen. Expert Opin. Biol. Ther. (2002) 2:75–85.
   PubMed Web of Science ®Google Scholar
• CONRY RM, ALLEN KO, LEE S, MOORE SE, SHAW DR,LOBUGLIO AF: Human autoantibodies to carcinoembryonic antigen (CEA) inducedby a vaccinia-CEA vaccine. Clin. Cancer Res. (2000) 6:34–41.
   PubMed Web of Science ®Google Scholar
• •Clinical trial (Phase I) of irmrtunogene therapy using recombinant vaccinia viruses encoding CEA gene for patients with CEA-positive adenocarcinoma. No severe adverse events.
   Google Scholar
• MARSHALL JL, HAWKINS MJ,TSANG KY et al.: Phase I study in cancer patients of replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J. Clin. Oncol (1999) 17:332–338.
   Google Scholar
• KIRN D: Oncolytic virotherapy for cancer with the adenovirus d11520 (ONYX-015): results of Phase I and II trials. Expert Opin. Biol. Ther. (2001) 1:525–538.
   PubMed Web of Science ®Google Scholar
• ••Clinical trial (Phase I and II) of genetherapy using genetically modified oncolytic virus (ONYX-015) for cancer patients. The virus was well-tolerated and local tumour regression rate was up to 14%.
   Google Scholar
• HABIB NA, SARRAF CE, MITRY RR et al.: E1B-deleted adenovirus (dll 520) gene therapy for patients with primary and secondary liver tumors. Hum. Gene Titer. (2001) 12:219–226.
   PubMed Web of Science ®Google Scholar
• REID T, GALANIS E, ABBRUZZESE J et al.: Hepatic arterial infusion of a replication-selective oncolytic adenovirus (d11520): Phase II viral, immunologic, and clinical endpoints. Cancer Res. (2002) 62:6070–6079.
   PubMed Web of Science ®Google Scholar
• BENNETT JJ, DELMAN KA, BURT BM et al.: Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther. (2002) 9:935–945.
   PubMed Web of Science ®Google Scholar
• VARGHESE S, RABKIN SD: Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. (2002) 9:967–978.
   PubMed Web of Science ®Google Scholar
• HORIG H, LEE DS, CONKRIGHT W et al.: Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother. (2000) 49:504–514.
   Google Scholar
• CHEN SH, KOSAI K, XU B et a/.: Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res. (1996) 56:3758–3762.
   Google Scholar
• OGAWA N, FUJIWARA T, KAGAWA S et al.: Novel combination therapy forhuman colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent. Int. J. Cancer (1997) 73:367–370.
   PubMed Web of Science ®Google Scholar
• MARUTA F, PARKER AL, FISHER KD et al.: Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer Gene Ther. (2002) 9:543–552.
   PubMed Web of Science ®Google Scholar
• •Use of phage display library (biopanning procedure) for tumour targeting in cancer gene therapy.
   Google Scholar
• HOLLON T: Researchers and regulatorsreflect on first gene therapy death. Nat. Med. (2000) 6:6.
   PubMed Web of Science ®Google Scholar
• •Report of the first death related to adenoviral vector in gene therapy.
   Google Scholar
• KAISER J: Gene therapy. Seeking the cause of induced leukemias in X-SCID trial. Science (2003) 299:495.
   Google Scholar
• RICHARDS CA, AUSTIN EA, HUBER BE: Transcriptional regulatory sequences of carcinoembryonic antigen:identification and use with cytosine deaminase for tumor-specific gene therapy. Hum. Gene The]: (1995) 6:881–893.
   PubMed Web of Science ®Google Scholar
• FISHER KD, STALLWOOD Y, GREEN NK, ULBRICH K, MAUTNER V, SEYMOUR LW: Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Thec (2001) 8:341–348.
   PubMed Web of Science ®Google Scholar
• ARAP W, PASQUALINI R, RUOSLAHTI E: Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science (1998) 279:377–380.
   PubMed Web of Science ®Google Scholar
• http://www.ncc.gajp/National Cancer Center: cancer statistics in Japan 2001. Age-adjusted death rates of malignant neoplasms by site, sex and calendar year (1950–1999).
   Google Scholar
• http://www.wiley.co.uk/wileychi/genmed Gene Therapy Clinical Trials. Website of Journal of Gene Medicine (2003).
   Google Scholar
• http://www.facs.org/dept/cancer/ncdb/ American College of Surgeons: National Cancer Data Base. Survival Reports, vi (2003).
   Google Scholar
• http://www4.od.nih.gov/oba/NIH OBA Gene Tranfser Clinical Trials Database. (2003).
   Google Scholar